Ark Genomic Revolution Etf Price To Earning
| ARKG Etf | USD 25.04 0.85 3.51% |
ARK Genomic Revolution fundamentals help investors to digest information that contributes to ARK Genomic's financial success or failures. It also enables traders to predict the movement of ARK Etf. The fundamental analysis module provides a way to measure ARK Genomic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ARK Genomic etf.
ARK |
ARK Genomic Revolution ETF Price To Earning Analysis
ARK Genomic's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current ARK Genomic Price To Earning | 41.86 X |
Most of ARK Genomic's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ARK Genomic Revolution is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, ARK Genomic Revolution has a Price To Earning of 41.86 times. This is much higher than that of the ARK ETF Trust family and significantly higher than that of the Health category. The price to earning for all United States etfs is notably lower than that of the firm.
ARK Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ARK Genomic's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of ARK Genomic could also be used in its relative valuation, which is a method of valuing ARK Genomic by comparing valuation metrics of similar companies.ARK Genomic is currently under evaluation in price to earning as compared to similar ETFs.
Fund Asset Allocation for ARK Genomic
The fund invests 99.63% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.Asset allocation divides ARK Genomic's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
ARK Fundamentals
| Price To Earning | 41.86 X | |||
| Price To Book | 3.26 X | |||
| Price To Sales | 7.63 X | |||
| Number Of Employees | 330 | |||
| Beta | 1.77 | |||
| Total Asset | 2.36 B | |||
| One Year Return | (13.20) % | |||
| Three Year Return | (33.70) % | |||
| Five Year Return | (4.70) % | |||
| Net Asset | 2.36 B | |||
| Last Dividend Paid | 1.05 | |||
| Equity Positions Weight | 99.63 % |
About ARK Genomic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ARK Genomic Revolution's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ARK Genomic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ARK Genomic Revolution based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with ARK Genomic
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ARK Genomic position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ARK Genomic will appreciate offsetting losses from the drop in the long position's value.Moving together with ARK Etf
| 0.78 | XLV | Health Care Select | PairCorr |
| 0.79 | VHT | Vanguard Health Care | PairCorr |
| 0.91 | IBB | iShares Biotechnology ETF | PairCorr |
| 0.83 | XBI | SPDR SP Biotech Aggressive Push | PairCorr |
| 0.74 | IHI | iShares Medical Devices | PairCorr |
Moving against ARK Etf
| 0.89 | TSJA | TSJA | PairCorr |
| 0.71 | DSJA | DSJA | PairCorr |
The ability to find closely correlated positions to ARK Genomic could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ARK Genomic when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ARK Genomic - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ARK Genomic Revolution to buy it.
The correlation of ARK Genomic is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ARK Genomic moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ARK Genomic Revolution moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ARK Genomic can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out ARK Genomic Piotroski F Score and ARK Genomic Altman Z Score analysis. You can also try the Stocks Directory module to find actively traded stocks across global markets.
The market value of ARK Genomic Revolution is measured differently than its book value, which is the value of ARK that is recorded on the company's balance sheet. Investors also form their own opinion of ARK Genomic's value that differs from its market value or its book value, called intrinsic value, which is ARK Genomic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARK Genomic's market value can be influenced by many factors that don't directly affect ARK Genomic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARK Genomic's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARK Genomic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARK Genomic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.